Cefazolin Lowers Kidney Injury in Staph Infections

A randomised trial found cefazolin linked to fewer acute kidney injuries than penicillin-class antibiotics in MSSA bloodstream infections.

Updated on Nov. 17, 2026 in Diseases — General

Economist-geometric style
Researchers found cefazolin was linked to fewer acute kidney injuries than flucloxacillin or cloxacillin in adults with MSSA bloodstream infections, with 90-day mortality noninferior. AI Illustration. Upload story photo >

The SNAP trial, published in the New England Journal of Medicine, compared cefazolin with flucloxacillin or cloxacillin in adults with methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. Cefazolin was associated with a lower rate of acute kidney injury, while 90-day mortality was noninferior between the two treatment groups.

Why it matters

Acute kidney injury is a serious complication of treating bloodstream infections, and the results may help inform future antibiotic choices for patients with serious MSSA infections. The findings add evidence on the safety profile of cefazolin relative to a commonly used alternative.

The trial enrolled 1,287 patients in the primary analysis, with acute kidney injury at 13.9% in the cefazolin group versus 19.6% in the comparator group (adjusted odds ratio 0.67). The 90-day mortality difference was not statistically decisive, with an adjusted odds ratio of 0.81 and a 95% credible interval of 0.59–1.12.

The players

New England Journal of Medicine

A long-established peer-reviewed medical journal published by the Massachusetts Medical Society, widely regarded as one of the most influential publications in clinical medicine.

The details

Researchers ran an open-label randomised study between February 2022 and August 2024 comparing cefazolin with flucloxacillin or cloxacillin in adults with MSSA bacteraemia. Acute kidney injury was assessed within 14 days of enrolment as a secondary safety outcome, while the primary outcome was all-cause mortality within 90 days.

Timeline

  1. February 2022: SNAP trial enrolment began.

  2. August 2024: SNAP trial enrolment ended.

  3. 2026: Results were published in the New England Journal of Medicine.

Health Landscape

The SNAP platform trial is a large, ongoing international effort to compare antibiotics for Staphylococcus aureus bloodstream infections, and this kidney-safety finding extends its comparison of standard agents. The result shifts attention toward nephrotoxicity as a deciding factor, alongside mortality, in choosing between beta-lactam options for MSSA bacteraemia.

For patients treated for MSSA bloodstream infections, the trial suggests cefazolin may carry a lower risk of acute kidney injury than penicillin-class alternatives. Treatment decisions remain with clinicians, who weigh infection severity, kidney function and other individual factors.

The takeaway

Kidney safety is a meaningful factor when choosing antibiotics for serious staph infections, not only mortality. Patients and clinicians should discuss the kidney-risk trade-offs of available options with their care team.

Further reading

Explore more on Diseases — General for broader context on treatment research.

Source note: This article includes information reported by European Medical Journal.